GHK-Cu Dosage: Topical vs Injectable
Last updated May 19, 2026 · Reviewed by Grey Peptides Editorial Board · ✓ Primary-sourced
← GHK-Cu encyclopedia entry · See also: BPC-157 dosage · Regulatory tracker
GHK-Cu has a genuinely strong topical/cosmetic evidence base — and essentially no validated injectable human dosing. There is no approved injectable product. Community injection figures below are research-only and provided for education, not as instructions for use. Do not assume skin-cream data justifies an injection.
The short version
GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine bound to copper) whose levels in the body decline with age. It is studied for collagen synthesis, wound healing, and anti-inflammatory signaling. The crucial framing point is that its two routes live in completely different evidence worlds: topical is well-trodden cosmetic territory, while systemic injection is a research-and-community practice with little human data.
Topical use (where the evidence is)
The bulk of GHK-Cu's reputation rests on topical cosmetic use — creams and serums for skin appearance, firmness, and fine lines, generally formulated at low percentages. This is the application with the most supportive data, and it is also the lowest-risk because it does not involve injecting an unregulated product. If your interest in GHK-Cu is skin, the topical route is where the evidence actually points.
Injectable community dosing (research-only)
Systemic, injectable GHK-Cu is used in some community and longevity protocols, typically reported as follows. These figures are descriptive, not prescriptive, and are not validated in humans.
| Parameter | Commonly reported (injectable) |
|---|---|
| Amount | ~1–2 mg/day |
| Route | Subcutaneous |
| Pattern | Time-limited cycles |
A specific caution applies here that does not apply to most peptides: GHK-Cu delivers copper, and copper has a relatively narrow margin between sufficiency and excess. Systemic dosing therefore raises questions about cumulative copper exposure that topical use largely sidesteps — another reason the injectable route is not a simple extrapolation from creams.
Where GHK-Cu stands legally
Injectable GHK-Cu was placed on the FDA 503A Category 2 list and, on April 15, 2026, was among the peptides removed from Category 2 after nominations were withdrawn — which does not confer approval. GHK-Cu (all routes) is slated for PCAC review by early 2027, with non-injectable GHK-Cu following a slightly separate path. See the Regulatory Status Tracker for the current picture.
Reconstitution basics (injectable)
Injectable GHK-Cu is supplied as a powder for reconstitution with bacteriostatic water. As with any compound dosed in milligrams from small vials, the dilution math is worth doing precisely — the Reconstitution Calculator handles it — but the math cannot address the deeper unknowns of an unregulated injectable or the copper-exposure question above.
Frequently asked questions
Can I just inject the cosmetic product?
No. Topical cosmetic formulations are not sterile injectables and are not designed or tested for injection. The routes are not interchangeable.
Why does copper matter?
Copper is an essential trace mineral with a narrow safe range; repeated systemic dosing of a copper-carrying peptide raises cumulative-exposure questions that topical use does not.
Is injectable GHK-Cu approved now that it's off Category 2?
No. Removal from Category 2 is a procedural step, not approval; the compound awaits PCAC review and is not an approved medicine.
Sources
- Pickart L, Margolina A. "Regenerative and protective actions of the GHK-Cu peptide." Int J Mol Sci. 2018;19:1987.
- U.S. FDA — 503A bulk drug substances list update and Category 2 removals, April 15, 2026; PCAC review schedule.
Medical disclaimer: Education only, not medical advice. Injectable GHK-Cu is not approved for human use; topical cosmetic use is a separate context. Dosing figures reflect community reports, not a recommendation. Do not self-administer; consult a licensed clinician.